Intravitreal brimonidine holds promise for slowing GA growthBrimonidine Drug Delivery System (Brimo DDS) in an intravitreally administered, sustained-release implant (Allergan) shows promise as a treatment for geographic atrophy (GA), secondary to age-related macular degeneration in a phase IIa clinical trial.
Using medications in pregnant glaucoma patientsMost of the medications, both new and old, we prescribe for glaucoma are quite safe—especially if we educate our patients to occlude their puncta.
Taking a closer look at low-tension glaucoma risk factors, treatment guidelinesA reasonable goal for patients with low-tension glaucoma patients is an IOP that’s 30% below the untreated baseline. However, some patients will continue to progress and may require single-digit target IOP goals.
It's rosacea, not acneNearly half of rosacea patients thought they had acne before being diagnosed. Learn how to explain the difference between rosacea and acne to patients and help them get the care they need.
Changing trends that may alter course of glaucoma practices
High IOP, corneal edema with unknown etiologyA few days ago, a 61-year-old white male presented with a gradual and painless loss of vision in his left eye.
Rosacea: Newer topical therapies are effective and well-tolerated
Rosacea: Newer topical therapies are effective and well-toleratedEmerging therapies for rosacea have a favorable side effect profile and address specific symptoms of the condition; brimonidine, for example, addresses background erythema while ivermectin addresses the papules and pustules.
Alcon IOP-lowering glaucoma treatment approved in EUAlcon Laboratories’ brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL (Simbrinza) eye drop formulation have been approved by the European Commission to decrease elevated IOP in adult patients with open-angle glaucoma or ocular hypertension.
Clues about rosacea pathogenesis spark treatment advances
Clues about rosacea pathogenesis spark treatment advancesAs researchers learn more about the pathogenesis of rosacea, they can better understand the benefits of certain medications and find opportunities for new therapies.
Mirvaso shows long-term efficacy for facial rednessResults of a long-term, multicenter study show that brimonidine is effective in treating moderate-to-severe facial erythema caused by rosacea.